Insights
Latest insights from Cortado Ventures’ Team, Founders and Network
Empowering Women in Legacy Sectors: Celebrating Innovators in Manufacturing and Supply Chain
Susan features Charu Thomas, Haley Keith, and Lisa Mullen.
Why We Invested: Cadenza Bio
Cortado Ventures invests in Cadenza Bio
Cody Merrill: A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad
CorriXR Therapeutics is the first spinout of ChristianaCare, a large Delaware-based healthcare system
Why We Invested: Lumata Health
Check out our latest “Why We Invested” blog
Nathaniel Harding: Year in Review and 2024 Outlook
Let’s look back at 2023 for VC and our firm to set the stage for an exciting 2024
Cadenza Bio, Inc. Secures $2.44M in Oversubscribed Series Seed Financing
Preclinical biotechnology company initially focusing on therapeutic drug development to promote remyelination in Multiple Sclerosis OKLAHOMA CITY, Dec. 14, 2023 /PRNewswire/ -- Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on developing...
Why We Invested: Moat Biotechnology
Our General Partner Mike Moradi articulates our commitment to Moat Biotechnology.
Cortado Ventures Invests in Teren, Inc.: Advancing Data-Driven Solutions for Climate and Terrain Risk Assessment
FOR IMMEDIATE RELEASE Oct. 11, 2023 Contact: Anthony Triana atriana@saxum.com (Direct) 405.818.0791 Cortado Ventures Invests in Teren, Inc.: Advancing Data-Driven Solutions for Climate and Terrain Risk Assessment OKLAHOMA CITY – Cortado Ventures, an early-stage...
Cortado Ventures Receives National News Coverage
AltAssets: Hefty exits help Cortado Ventures score huge fund size increase for sophomore raise Wall Street Journal VC Pro: VC Daily: What the New IPOs Mean for Late-Stage Market; Instacart Pops StrictlyVC: Musk gets probed, Neuralink searches for recruits, and...